Article Figures & Data
- Figure 1
Study flow chart.
- Figure 2
Comparisons of three included clinical trials. AcT, Tenecteplase in Patients With Acute Ischaemic Stroke; DWI, diffusion-weighted imaging; EVT, endovascular treatment; FLAIR, fluid-attenuated inversion recovery; NIHSS, National Institutes of Health Stroke Scale; NOR-TEST, Norwegian Tenecteplase Stroke; rhTNK-tPA, recombinant human tissue-type plasminogen activator; TRACE-2, Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Ebemts-2.
- Figure 3
Risk of bias assessment for efficacy and safety outcomes. Risk of bias legend. AcT, Tenecteplase in Patients With Acute Ischaemic Stroke; D, Bias due to deviations from intended interventions; Me, Bias in measurement of the outcome; Mi, Bias due to missing outcome data; NOR-TEST, Norwegian Tenecteplase Stroke; O, overall risk of bias; R, bias arising from the randomisation process; S, bias in selection of the reported result; TRACE-2, Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-2.
- Figure 4
Forest plot for efficacy outcomes. (A) mRS 0–1, (B) mRS 0–2, (C) mRS 5–6, (D) major neurological improvement. AcT, Tenecteplase in Patients With Acute Ischaemic Stroke; mRS, modified Rankin Scale; NOR-TEST, Norwegian Tenecteplase Stroke; RD, risk difference; TRACE-2, Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-2.
- Figure 5
Forest plot for safety outcomes. (A) Symptomatic intracerebral haemorrhage, (B) Parenchymal haematoma type 2, (C) any intracerebral haemorrhage, (D) 90-day death. AcT, Tenecteplase in Patients With Acute Ischaemic Stroke; NOR-TEST indicates Norwegian Tenecteplase Stroke; TRACE-2, Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-2.
Supplementary Materials
Supplementary data
Additional Files
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
